Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+Esophageal Carcinoma: the TRAP Study
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Acronyms TRAP
- 07 Jun 2017 Biomarkers information updated
- 30 May 2017 Status changed from recruiting to completed.
- 26 Jul 2016 Planned End Date changed from 1 Jan 2016 to 1 Apr 2017.